Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04995523 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
A Phase 1 study of Non-Small-Cell Lung Carcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
- 20
- Study locations
NCT04995523 is a Phase 1 study of Non-Small-Cell Lung Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 210 participants, roughly in line with the 229-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT04995523, a Phase 1 study of Non-Small-Cell Lung Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Conditions Studied
Interventions
- DRUG AZD2936
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Anderlecht
- Research Site - Leuven
- Research Site - Florianópolis
- Research Site - Natal
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - São Paulo
- Research Site - Chengdu
- Research Site - Chongqing
- Research Site - Wuhan
- Research Site - Copenhagen
- Research Site - Dijon
- Research Site - Toulouse
California
- Research Site - Orange
Illinois
- Research Site - Chicago
Maryland
- Research Site - Baltimore
Minnesota
- Research Site - Rochester
Texas
- Research Site - Houston
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2028-03-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04995523
The ClinicalTrials.gov registry entry for NCT04995523 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 229-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AZD2936 is the first listed.
NCT04995523 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT04995523 about?
NCT04995523 is a clinical study titled "A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC". This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
What is the current status of trial NCT04995523?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2021-09-14. Estimated completion is 2028-03-16.
What conditions does trial NCT04995523 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT04995523?
The interventions under investigation include: AZD2936 (DRUG).
Who is sponsoring clinical trial NCT04995523?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04995523 being conducted?
This trial has 20 study locations across California, Illinois, Maryland, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Retifanlimab and Ruxolitinib In Solid Malignancies
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RECRUITING · Phase 1
-
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
ACTIVE NOT RECRUITING · Phase 1
-
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.